Combined targeting of Src and ER completely abrogates the invasive behavior of tamoxifen resistant MCF-7 and T47D breast cancer cell lines [12] and reduces cell growth and survival of long-term estrogen deprived (LTED) cells [13]. The gene discussed is ESR1; the disease is breast carcinoma.